ORDERINGINFORMATION
CatalogNo. 16801 | CloneNo. VP10-115.2 | MAbSubtype IgG1 | Size 100ug,500ug | LibraryPackNo. 168101 | 100ug/clone All5clones |
16802 | VP10-201.7 | IgG1 | 100ug,500ug | ||
16803 | VP10-234.5 | IgG1 | 100ug,500ug | ||
16804 | VP13-607.1 | IgG1 | 100ug,500ug | ||
16805 | VP13-615.3 | IgG1 | 100ug,500ug |
Format:ProteinG-purifiedantibodyinPBS,pH7.4.
BACKGROUND
Valproicacidisprimarilyusedtotreatepilepsyandbipolardisorderandtopreventmigraineheadaches.Ithasrecentlybeenshowntoprotectagainstaseizure-inducedreductioninphosphatidylinositol(3,4,5)-trisphosphate(PIP3)asapotentialtherapeuticmechanism.Inaddition,itsanticonvulsanteffecthasbeenattributedtotheblockadeofvoltage-dependentsodiumchannelsandincreasedbrainlevelsofgamma-aminobutyricacid(GABA).
Valproicacidwasfirstmadein1881andcameintomedicalusein1962.ItisontheWorldHealthOrganization'sListofEssentialMedicines.
SPECIFICATIONSUMMARY
Antigen:ValproicacidconjugatedtoKLH.
HostSpecies:Mouse
Specificity:Theseantibodiesrecognizevalproicacid.
APPLICATIONS
TheseantibodieshavebeenqualifiedforuseinELISAtodetectvalproicacid.
DILUTIONINSTRUCTIONS
DiluteinPBSormediumthatisidenticaltothatusedintheassaysystem.
STORAGEANDSTABILITY
Theseantibodiesarestableforatleastone(1)yearat-20oCto-70oC.Storeproductinappropriatealiquotstoavoidmultiplefreeze-thawcycles.
Forinvitroinvestigationaluseonly.Notforuseintherapeuticordiagnosticprocedures.
